Roche Tasmar anti-Parkinson's therapy reduces "off" time 20%-30%, U.K. labeling states.
Executive Summary
ROCHE TASMAR REDUCES PARKINSON's "OFF" TIME 20%-30%, U.K. labeling for the therapy states. Tasmar (tolcapone) was approved by the European Medicine Evaluation Agency Aug. 27 as an adjunct to levodopa/carbidopa treatment and has become available in Germany and the U.K., Roche announced. Tasmar is the first catechol-O-methyltransferase inhibitor to come to market and will soon be available in other European countries, the company stated.
You may also be interested in...
Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA Skin Infections Guidance Spurs Debate On Endpoint Relevance
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Shire Hopes To Sow Future Deals With $50M Venture Fund
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth